HOME >> MEDICINE >> NEWS
HHS announces contracts for developing a new anthrax vaccine

HHS Secretary Tommy G. Thompson today announced that the National Institute of Allergy and Infectious Diseases (NIAID) has awarded two companies contracts designed to spur development of a new anthrax vaccine. The two contracts total $22.5 million through Fiscal Year 2003.

"There is an urgent need to devise more effective measures to protect U.S. citizens from the harmful effects of anthrax spores used as instruments of terror," said Secretary Thompson. "These awards represent the first step toward our goal of securing an initial 25 million doses of an improved anthrax vaccine for our emergency stockpile."

"Vaccines are the best method of protecting the public against infectious diseases," said NIAID Director Anthony S. Fauci, M.D. "At NIAID, one of our top priorities is to work with industry to create new and improved vaccines against possible agents of bioterrorism. These vaccines must be suitable for civilian populations of varying ages and health status. In addition, the vaccines must be safe, easy to administer, and capable of inducing an immediate protective immune response."

The currently licensed anthrax vaccine, administered almost exclusively to military personnel, must be given in six doses over 18 months. The new vaccine will be required to provide immunity to inhalation anthrax in three or fewer doses, which is expected to reduce the administration time. It is hoped that a quicker administration time and other technological improvements would allow the vaccine to protect individuals from anthrax spores even if the vaccine was given shortly after exposure.

The companies awarded contracts today are Avecia, of Manchester, United Kingdom, and VaxGen Inc., of Brisbane, California.

Under the terms of the contracts, the companies will base their vaccine candidates on a promising vaccine concept. The vaccine will contain the protective antigen of the anthrax bacterium, which will be produced with recombinant DNA techno
'"/>

Contact: Jeff Minerd
jminerd@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
3-Oct-2002


Page: 1 2

Related medicine news :

1. The Gerontological Society of America announces Hartford Fellowship recipients
2. TB Alliance announces new drug discovery program with GlaxoSmithKline
3. ASGE announces grant recipients in annual research awards program
4. Novartis announces collaboration with Bayer for EMSELEX
5. American College of Chest Physicians announces new Critical Care Institute
6. Eyetech Pharmaceuticals, Inc. announces macugen data on treating macular degeneration
7. Department of Energy announces new agreement with USC, national labs and private company
8. ACP announces international medical fellowship
9. St. Jude Medical announces CRT patients showed improvement in the RHYTHM ICD study
10. St. Jude Medical announces PAVE and DINAMIT clinical trial results
11. National Inventors Hall of Fame announces 2004 class of inventors

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/20/2017)... 2017 (PRWEB) , ... July ... ... global provider of enterprise-grade IT operations analytics and application performance monitoring (APM) ... of world’s largest healthcare services providers. , According to Peter Ohrenberger, sales ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... For individuals ... utmost importance. The adjustable beds used in such facilities are specially designed to accommodate ... adequate arm support. , An inventor from Rochester, Ind., has invented the patent-pending ...
(Date:7/20/2017)... ... July 20, 2017 , ... Team Type 1 Foundation, a ... for everyone affected by diabetes, is teaming up with a Microsoft Corp. employee-led hackathon ... off on July 24th. , “Team Type 1’s mission overlaps seamlessly with Microsoft’s ...
(Date:7/20/2017)... ... July 20, 2017 , ... Vixiar Medical, Inc. , ... systems for monitoring cardiopulmonary diseases, announced today that it has raised seed round ... submissions and fund final engineering and initial production of the Company’s first product, ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... FDAnews Webinar**, Aug. 9, 2017 — 1:30 p.m. – 3:00 p.m. ET, ... inspections and boosting quality. , It’s known as the “CY2016 Annual FDA Medical ...
Breaking Medicine News(10 mins):
(Date:7/19/2017)... 2017  Mako Medical Laboratories partnered with Secretary Strickland, ... Assistance Fund (MFA) to bring 140 soldiers back home ... their families one last time before being deployed. Mako ... and logistics needed for these soldiers. "Mako Medical Laboratories ... families. We just wish we could bring them all ...
(Date:7/13/2017)... , July 13, 2017  Centurion Medical Products, a leader in ... DisImpactor ® fecal impaction removal device for hospice patient care. ... Centurion Medical ... Patient pain management and emotional comfort ... can help alleviate patient pain while preventing unneeded emergency department admission ...
(Date:7/11/2017)... , July 11, 2017 Zymo Research Corp., also known as ... can quantify biological aging in a precise manner using the myDNAge ™ ... Horvath , a professor of human genetics and biostatistics at the ... of Public Health , Zymo Research,s proprietary DNAge ™ technology is ... ...
Breaking Medicine Technology:
Cached News: